SuperworthZymeworks EPS ZYME
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$2.02
- Latest quarter, Q2 FY26
- −$0.62
- −2167% on a year earlier
- Fiscal year 2025
- −$1.08
Zymeworks' earnings per share was −$2.02 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.62, down 2167% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.08 | n/a |
| FY2024 | −$1.61 | n/a |
| FY2023 | −$1.74 | −199% |
| FY2022 | $1.76 | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.62 | −2167% | −$2.02 | |
| Q1 FY26 | −$0.59 | n/a | −$1.37 | |
| Q4 FY25 | −$0.55 | n/a | −$1.08 | |
| Q3 FY25 | −$0.26 | n/a | −$0.84 | |
| Q2 FY25 | $0.03 | n/a | −$0.97 | |
| Q1 FY25 | −$0.30 | n/a | −$1.49 | |
| Q4 FY24 | −$0.31 | n/a | −$1.61 | |
| Q3 FY24 | −$0.39 | n/a | −$1.50 | |
| Q2 FY24 | −$0.49 | n/a | −$1.52 | |
| Q1 FY24 | −$0.42 | n/a | −$1.79 | |
| Q4 FY23 | −$0.20 | −104% | −$1.74 | |
| Q3 FY23 | −$0.41 | n/a | $3.10 |
Against its peers
Companies in Drug Manufacturers - General nearest Zymeworks' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ZYMEZymeworks | −$2.02 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| NRIXNurix Therapeutics | $2.31 | |
| OMEROmeros | $1.52 | |
| OGNOrganon | $0.77 | −71% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Zymeworks
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.